dbo:abstract
|
- Laquinimod je experimentální imunomodulátor, vyvíjený farmaceutickými společnostmi a Teva Pharmaceuticals. Je určen k perorální léčbě pacientů s roztroušenou sklerózou (RS). Jeho chemický vzorec je C19H17ClN2O3. Laquinimod je nástupcem neúspěšného experimentálního imunomodulátoru , vyvíjeného rovněž společností Active Biotech. Imunomodulátor byl zkoumán ve dvou studiích ve II. fázi klinických testů za využití opakovaných snímků magnetické rezonance (MRI). Podle výsledků se zdá být laquinimod schopný redukovat aktivitu RS. U obou studií se však projevily odlišné reakce na podanou dávku laquinimodu. Od roku 2008 je imunomodulátor ve III. fázi klinických testů. (cs)
- Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI. However, the response to a given dose was discrepant between both studies. Phase III studies for MS started in December 2007. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses in MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis. On May 7, 2013 laquinimod was approved by the Russian Ministry of Health (the FDA analog) as a treatment for relapsing-remitting multiple sclerosis (RRMS) under the brand name Nerventra. (en)
|
dbo:iupacName
|
- 5-Chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide (en)
|
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 7062 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:imagefile
| |
dbp:pin
| |
dbp:verifiedfields
| |
dbp:verifiedrevid
| |
dbp:watchedfields
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
gold:hypernym
| |
rdf:type
| |
rdfs:comment
|
- Laquinimod je experimentální imunomodulátor, vyvíjený farmaceutickými společnostmi a Teva Pharmaceuticals. Je určen k perorální léčbě pacientů s roztroušenou sklerózou (RS). Jeho chemický vzorec je C19H17ClN2O3. Laquinimod je nástupcem neúspěšného experimentálního imunomodulátoru , vyvíjeného rovněž společností Active Biotech. Od roku 2008 je imunomodulátor ve III. fázi klinických testů. (cs)
- Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI. However, the response to a given dose was discrepant between both studies. (en)
|
rdfs:label
|
- Laquinimod (cs)
- Laquinimod (en)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |